Eucrates Biomedical Acquisition Corp.
Eucrates Biomedical Acquisition Corp. (EUCR) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001822929 · EUCR · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001822929 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Eucrates Biomedical Acquisition Corp. (NASDAQ: EUCR) has submitted 74 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Financial Services sector company with CIK 0001822929, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Eucrates Biomedical Acquisition Corp.'s most comprehensive regulatory disclosure. The most recent Eucrates Biomedical Acquisition Corp. 10-K was filed on 2023-04-13 for fiscal year ending 2023. Historical EUCR 10-K annual reports are available from 2020 through 2023.
Investors researching Eucrates Biomedical Acquisition Corp. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
EUCR SEC Filings · 8 questionsEucrates Biomedical Acquisition Corp. (EUCR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 74 filings and access original documents at no cost. Eucrates Biomedical Acquisition Corp.'s CIK is 0001822929.